These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20415520)

  • 1. Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation.
    Wang W; Ghandi A; Liebes L; Louie SG; Hofman FM; Schönthal AH; Chen TC
    J Neurosurg; 2011 Mar; 114(3):689-94. PubMed ID: 20415520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
    Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
    Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
    Chen TC; Su S; Fry D; Liebes L
    Cancer; 2003 May; 97(9 Suppl):2363-73. PubMed ID: 12712458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered irinotecan metabolism in a patient receiving phenytoin.
    Mathijssen RH; Sparreboom A; Dumez H; van Oosterom AT; de Bruijn EA
    Anticancer Drugs; 2002 Feb; 13(2):139-40. PubMed ID: 11901305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
    Metz MZ; Gutova M; Lacey SF; Abramyants Y; Vo T; Gilchrist M; Tirughana R; Ghoda LY; Barish ME; Brown CE; Najbauer J; Potter PM; Portnow J; Synold TW; Aboody KS
    Stem Cells Transl Med; 2013 Dec; 2(12):983-92. PubMed ID: 24167321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan therapy in adults with recurrent or progressive malignant glioma.
    Friedman HS; Petros WP; Friedman AH; Schaaf LJ; Kerby T; Lawyer J; Parry M; Houghton PJ; Lovell S; Rasheed K; Cloughsey T; Stewart ES; Colvin OM; Provenzale JM; McLendon RE; Bigner DD; Cokgor I; Haglund M; Rich J; Ashley D; Malczyn J; Elfring GL; Miller LL
    J Clin Oncol; 1999 May; 17(5):1516-25. PubMed ID: 10334539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
    Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
    Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
    Prados MD; Yung WK; Jaeckle KA; Robins HI; Mehta MP; Fine HA; Wen PY; Cloughesy TF; Chang SM; Nicholas MK; Schiff D; Greenberg HS; Junck L; Fink KL; Hess KR; Kuhn J;
    Neuro Oncol; 2004 Jan; 6(1):44-54. PubMed ID: 14769140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.
    Crews KR; Stewart CF; Jones-Wallace D; Thompson SJ; Houghton PJ; Heideman RL; Fouladi M; Bowers DC; Chintagumpala MM; Gajjar A
    Clin Cancer Res; 2002 Jul; 8(7):2202-9. PubMed ID: 12114421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
    Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
    Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.
    Gomez-Manzano C; Alonso MM; Yung WK; McCormick F; Curiel DT; Lang FF; Jiang H; Bekele BN; Zhou X; Alemany R; Fueyo J
    Clin Cancer Res; 2006 Jan; 12(2):556-62. PubMed ID: 16428500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.
    Storm PB; Renard VM; Moriarity JL; Tyler B; Wilentz RE; Brem H; Weingart JD
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):361-7. PubMed ID: 15197484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma.
    Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Saito Y; Matsumura Y
    Int J Cancer; 2009 Jun; 124(11):2505-11. PubMed ID: 19189401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.
    Gajjar A; Chintagumpala MM; Bowers DC; Jones-Wallace D; Stewart CF; Crews KR
    Cancer; 2003 May; 97(9 Suppl):2374-80. PubMed ID: 12712459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
    Bissery MC; Vrignaud P; Lavelle F; Chabot GG
    Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
    Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
    Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.
    Nakajima TE; Yanagihara K; Takigahira M; Yasunaga M; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Mihara K; Ochiya T; Matsumura Y
    Cancer Res; 2008 Nov; 68(22):9318-22. PubMed ID: 19010905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Convection-enhanced delivery of SN-38-loaded polymeric micelles (NK012) enables consistent distribution of SN-38 and is effective against rodent intracranial brain tumor models.
    Zhang R; Saito R; Mano Y; Sumiyoshi A; Kanamori M; Sonoda Y; Kawashima R; Tominaga T
    Drug Deliv; 2016 Oct; 23(8):2780-2786. PubMed ID: 26330269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model.
    Wang W; Cho HY; Rosenstein-Sisson R; Marín Ramos NI; Price R; Hurth K; Schönthal AH; Hofman FM; Chen TC
    J Neurosurg; 2018 Mar; 128(3):695-700. PubMed ID: 28409734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPLC analysis and extraction method of SN-38 in brain tumor model after injected by polymeric drug delivery system.
    Nittayacharn P; Manaspon C; Hongeng S; Nasongkla N
    Exp Biol Med (Maywood); 2014 Dec; 239(12):1619-29. PubMed ID: 24990485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.